On March 3, 2025, BeiGene secured another approval for its anti-PD-1 antibody, TEVIMBRA, as the FDA granted clearance for its use in combination with platinum-based chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.
TEVIMBRA is also approved in the US as a standalone treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma who have previously received systemic chemotherapy without a PD-(L)1 inhibitor. Additionally, it is authorized in combination with chemotherapy as a first-line treatment for adults with gastric an...
